Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27900170 | 0.83 | EPHX2 (0.51) | NAMPTEPHX2HTR2A | |
| SCHEMBL3959408 | 0.82 | EPHX2 (0.50) | NAMPTEPHX2HTR2A | |
| SCHEMBL3088045 | 0.82 | DRD3 (0.55) | NAMPTEPHX2HTR2A | |
| SCHEMBL3079841 | 0.82 | DRD3 (0.55) | NAMPTEPHX2HTR2A | |
| SCHEMBL3087492 | 0.81 | DRD3 (0.51) | NAMPTEPHX2HTR2A | |
| Cyclopropane SCHEMBL14715705 | 0.81 | EPHX2 (0.55) | NAMPTEPHX2ADRB2 | |
| SCHEMBL3074454 | 0.81 | DRD2 (0.56) | NAMPTEPHX2HTR2A | |
| SCHEMBL3074452 | 0.81 | DRD2 (0.56) | NAMPTEPHX2HTR2A | |
| Trifluoroacetic Acid SCHEMBL3091025 | 0.80 | HRH1 (0.46) | NAMPTADRB2CCR3HRH1HTR2A | |
| Trifluoroacetic Acid SCHEMBL3091028 | 0.80 | HRH1 (0.46) | NAMPTADRB2CCR3HRH1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079693-B1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-7795437-B2 | Ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20080103174-A1 | ETHER DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103174-A1 | ETHER DERIVATIVES | GABRE, BDNF, ADH1A | NAMPT 3982/4885EPHX2 602/4885ADRB2 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.